JT2

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/526,978
Filing Date	March 7, 2005
First Named Inventor	Daggett, et al.
Art Unit	1645
Examiner Name	
Total Number of Pages in This Submission: 15	Attorney Docket Number: MS0023P

ENCLOSURES *(Check all that apply)*

- ☒ Fee Transmittal Form
  - ☐ Fee Attached
- ☐ Amendment/Reply
  - ☐ After Final
  - ☐ Affidavits/declaration(s)
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☒ Information Disclosure Statement
- ☐ Certified Copy of Priority Document(s)
- ☐ Response to Missing Parts/ Incomplete Application
  - ☐ Response to Missing Parts under 37 CFR 1.52 or 1.53
- ☐ Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition
- ☐ Petition to Convert to a Provisional Application
- ☐ Power of Attorney, Revocation Change of Correspondence Address
- ☐ Terminal Disclaimer
- ☐ Request for Refund
- ☐ CD, Number of CD(s) _____
- ☐ After Allowance Communication to Technology Center (TC)
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to TC **(Appeal Notice, Brief, Reply Brief)**
- ☐ Proprietary Information
- ☐ Status Letter
- ☐ Other Enclosure(s) (please Identify below):

Remarks

SUBSTITUTE PRELIMINARY AMENDMENT
1449 FORM AND REFERENCES

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Name	Joan E. Switzer	*Registration No. (Attorney/Agent)*	34,740
Signature	Joan E Switzer	Date	7/19/07

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on this date: July 19, 2007

Typed or printed name	Nancy E. Yorke		
Signature	Nancy E Yorke	Date	July 19, 2007

PATENT Case No. MS0023P

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Daggett, et al.



Serial No. 10/526,978

Filed: March 7, 2005

For: NUCLEIC ACID SEQUENCES ENCODING NOVEL POINT MUTATIONS ON mGluR2 AND mGluR3, POLYPEPTIDES WITH SAID MUTATIONS, AND METHODS OF USING SAID POLYPEPTIDES, TO IDENTIFY, PREDICT AND EVALUATE SPECIFIC, SELECTIVE MODULATORS WHOSE ASSOCIATION TO mGluR2 OR mGluR3 IS EFFECTED BY SAID MUTATIONS

Art Unit: 1645

Examiner: Zeman

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).

2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.

4. Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

By Nancy Leyden Date July 19, 2007

PATENT Case No. MS0023P

INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

	RELATED APPLICATION	
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE

If this is inconvenient, additional copies will be submitted upon request.

6. In accordance with 37 C.F.R. 1.97, (check one)

☐ the attached information is filed within three months of the filing date of the captioned case.

☑ the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.

☐ the attached information is filed before the mailing of a first Office action after the filing of a request for continued examination under §1.114.

☐ the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action, Notice of Allowance, or an action that otherwise closes prosecution in the application. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).

☐ each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.

☐ each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart application *and this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of the information disclosure statement.*

☐ no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,

By: Joan E. Switzer
Attorney For Applicant(s)
Reg. No. 34,740
MERCK & CO., INC.
Patent Dept., RY60-30
P.O. Box 2000
Rahway, N.J. 07065-0907
(732)594-5616
Date: 7/19/07

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3

COMPLETE IF KNOWN	
Application Number	10/526,978
Filing Date	March 7, 2005
First Named Inventor	Daggett, et al.
Group Art Unit	1645
Examiner Name	Zeman
Attorney Docket Number	MS0023P

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		5,521,297		Daggett, et al.	05/28/1996
		5,807,689		Daggett, et al.	09/15/1998
		6,001,581		Johnson, et al.	12/14/1999
		6,017,697		Burnett, Jr., et al.	01/25/2000
		6,387,655 B1		Burnett, et al.	05/14/2002
		6,413,764		Daggett, et al.	07/02/2002
		6,485,919		Daggett, et al.	11/26/2002

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
			WO 96/06167		Ciba-Geigy AG	02/25/1996
			EP 0 711 832 A2		Eli Lilly and Company	05/16/1996
			WO 01/46691 A1		Biosignal Packard Inc.	06/28/2001

Examiner Signature		Date Considered	

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

COMPLETE IF KNOWN	
Application Number	10/526,978
Filing Date	March 7, 2005
First Named Inventor	Daggett, et al.
Group Art Unit	1645
Examiner Name	Zeman
Attorney Docket Number	MS0023P

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
		Baez, et al., "Molecular Mapping of a Subtype Selective Site For Positive Allosteric Modulation of the mGlu2 Receptor," Neuropharmacology, Vol. 43, 2002, pp. 273-318.
		Bond, et al., "Neuroprotective Effects of LY379268, a Selective mGlu2/3 Receptor Agonist: Investigations into Possible Mechanism of Action In Vivo", The Journal of Pharmacology and Experimental Therapeutics," Vol. 294, No. 3, 2000, pp. 800-809.
		Christopoulos, et al., "G Protein-Coupled Receptor Allosterism and Complexing," Pharmacological Review, Vol. 54, No. 2, 2002, pp. 323-374.
		Escribano, et al., "(2S,4S)-2-Amino-4-(2.2-Diphenylethyl)Pentanedioic Acid Selective Group 2 Metabotropic Glutamate Receptor Antagonist", Bioorganic & Medicinal Chemistry Letters, Vol. 8, 1998, pp. 765-770.
		Helton, et al., "Anxiolytic and Side-Effect Profile of LY354740: A Potent, Highly Selective, Orally Active Agonist for Group II Metabotropic Glutamate Receptors," The Journal of Pharmacology and Experimental Therapeutics, Vol. 284, No. 2, 1998, pp. 651-660.
		Johnson, et al., "Subtype-Selective Positive Allosteric Modulators of the Metabotropic Glutamate 2 Receptor: In Vitro and In Vivo Characterization of Novel mGlu2 Potentiators", Neuropharmacology, Vol. 43, 2002, pp. 273-318.
		Johnson, et al., "Discovery of Allosteric Potentiators for the Metabotropic Glutamate 2 Receptor: Synthesis and Subtype Selectivity of N-(4-(2-Methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl) pyrid-3-ylmethyl- amine," J. Med. Chem., Vol. 46, 2003, pp. 3189-3192.
		Kingston, et al., "LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors," Neuropharmacology, Vol. 37, 1998, pp. 1-12.
		Mary, et al., "A Cluster of Basic Residues in the Carboxyl-terminal Tail of the Short Metabotropic Glutamate Receptor 1 Variants Impairs Their Coupling to Phospholipase C," The Journal of Biological Chemistry, Vol. 273, No. 1, January 2, 1998, pp. 425-432.
		Masu, et al., "Sequence and expression of a metabotropic glutamate receptor," Nature, Vol. 349, 28 February 1991, pp. 760-765.
		Mukhopadhyaya, et al., "Synthesis of N1-Substituted Analogues of (2R,4R)-4-Amino-pyrrolidine-2,4-dicarboxylic Acid as Agonists, Partial Agonists, and Antagonists of Group II Metabotropic Glutamate Receptors," Bioorganic Medicinal Chemistry Letters, Vol. 11, 2001, pp. 1919-1924.
		Perroy, et al., "The C Terminus of the Metabotropic Receptor Subtypes 2 and 7 Specifies the Receptor Signaling Pathways," The Journal of Biological Chemistry, Vol. 276, No. 49, December 7, 2001, pp. 45800-45805.
		Nakazato, et al., "Synthesis ,SARs, and Pharmacological Characterization of 2-Amino-3 or 6-fluorobicyclo[3.1.0]heane-2,6-dicarboxylic Acid Derivatives as Potent, Selective, and Orally Active . . .," J. Med. Chem., Vol. 43, 2000, pp. 4893-4909.
		Naples, et al., "Pharmacological profiles of the metabotropic glutamate receptor ligands [3H]L-AP4 and [3H]CPPG," Neuropharmacology, Vol. 40, 2001, pp. 170-177.
		Ornstein, et al., "2-Substituted (2SR)-2-Amino-2-((1,SR,2SR)-2-carboxycycloprop-1-yl)glycines as Potent and Selective Antagonists of Group II Metabotropic Glutamate Receptors," J. Med. Chem., Vol. 41, 1998, pp. 346-357.

Examiner Signature		Date Considered	

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form " IDS Form" (IDS Folder), Merck & Co., Inc., 06/28/2007

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 3

COMPLETE IF KNOWN	
Application Number	10/526,978
Filing Date	March 7, 2005
First Named Inventor	Daggett, et al.
Group Art Unit	1645
Examiner Name	Zeman
Attorney Docket Number	MS0023P

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
		Schaffhauser, et al., "Pharmacological Characterization and Identification of Amino Acids Involved in the Positive Modulation of Metabotropic Glutamate Receptor Subtype 2", Molecular Pharmacology, Vol. 64, No. 4, 2003, pp. 798-810.
		Schoepp, et al., "Pharmacological and functional characteristics of metabotropic excitatory amino acid receptors," TiPS, Vol. 11, December 1990, pp. 508515.
		Schoepp, et al., "1S,3R-ACPD-sensitive (metabotropic)[3H]glutamate receptor binding in membranes," Neuroscience Letters, Vol. 145, 1992, pp. 100-104.
		Schoepp, et al., "Metabotropic glutamate receptors in brain function and pathology", TiPS, Vol. 141, January 1993, pp. 13-20.
		Takahashi, et al., "Role of the Large Extracellular Domain of Metabotropic Glutamate Receptors in Agonist Selectivity Determination," Journal of Biological Chemistry, Vol. 268, No. 26, September 15, 1993, pp. 19341-19345.
		Tanabe, et al., "A Family of Metabotropic Glutamate Receptors," Neuron, Vol. 8, January 1992, pp. 169-179.

Examiner Signature		Date Considered	

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.